The convalescent sera option for containing COVID-19

Journal of Clinical Investigation

Volumn 130, Issue 4, 2020, Pages 1545-1548

  Casadevall, Arturo ^a   Pirofski, Liise Anne ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; CLINICAL EFFECTIVENESS; CONVALESCENCE; CORONAVIRUS DISEASE 2019; EXPERIENCE; HISTORICAL RESEARCH; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; META ANALYSIS (TOPIC); NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SERUM; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS NEUTRALIZATION; ADVERSE EVENT; BETACORONAVIRUS; BLOOD; BLOOD DONOR; CORONAVIRUS INFECTION; HISTORY; IMMUNOLOGY; PANDEMIC; PROCEDURES; RISK ASSESSMENT; VIRUS PNEUMONIA;

ANTIBODIES, VIRAL; BETACORONAVIRUS; BLOOD DONORS; CORONAVIRUS INFECTIONS; COVID-19; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION, PASSIVE; PANDEMICS; PNEUMONIA, VIRAL; RISK ASSESSMENT; SARS-COV-2;

EID: 85082421300     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI138003     Document Type: Review

References (34)

1. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150-161.
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695-703.
3. Zhang JS, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. JMedVirol. 2005;77(2):147-150.
4. Beigel JH, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18(4):410-418.
5. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. JInfectDis. 1995;171(6):1387-1398.
6. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474-478.
7. Casadevall A, Scharff MD. Serum therapy revisted: animal models of infection and development of passive antibody therapy. AntimicrobAgents Chemother. 1994; 38(8):1695-1702.
8. Park WH. Therapeutic use of antipoliomyelitits serum in preparalytic cases of poliomyelitis. JAMA. 1932;99:1050-1053.
9. Park WH, Freeman RG. The prophylactic use of measles convalescent serum. JAMA. 1926;87(8):556-558.
10. Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health Nations Health. 1935;25(5):595-598.
11. Rambar AC. Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis. Am J Dis Child. 1946;71:1-13.
12. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38(4 suppl):e66-e73.
13. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599-609.
14. Hung IF, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456.
15. Sahr F, et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. JInfect. 2017;74(3):302-309.
16. Kraft CS, et al. The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496-502.
17. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006;12(6):489.
18. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1451.
19. Wu XX, Gao HN, Wu HB, Peng XM, Ou HL, Li LJ. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis. 2015;41:3-5.
20. Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-46.
21. Yeh KM, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. JAntimicrobChemother. 2005;56(5):919-922.
22. Ko JH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther (Lond). 2018;23(7):617-622.
23. Arabi YM, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis. 2016;22(9):1554-1561.
24. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548.
25. Jenks JA, Goodwin ML, Permar SR. The roles of host and viral antibody fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity. Front Immunol. 2019;10:2110.
26. Gunn BM, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. CellHostMicrobe. 2018;24(2):221-233.e5.
27. China puts 245 COVID-19 patients on convalescent plasma therapy. News release. Xinhua. February 28, 2020. Accessed March 10, 2020. http://www.xinhuanet.com/english/202002/28/c_138828177.htm.
28. Gajic O, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-891.
29. Wan Y, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015-19.
30. Mair-Jenkins J, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90.
31. Crowe JE, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. JImmunol. 2001;167(7):3910-3918.
32. Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303.
33. Hopkins JS. Drugmaker Takeda Is Working on Coronavirus Drug. Wall Street Journal. https://www.wsj.com/articles/drugmakertakeda-is-working-on-coronavirusdrug-11583301660. Published March 4, 2020. Accessed March 10, 2020.
34. McGuire LW, Redden WR. The use of convalescent human serum in influenza pneumonia-a preliminary report. Am J Public Health (N Y). 1918;8(10):741-744.